Evaluating the impact of resident involvement during the laparoscopic nephrectomy

por Privé, Bastiaan, Kortleve, Michael, van Basten, Jean-Paul
Publicado 2019

Head-to-Head Comparison of (68)Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients

por Schilham, Melline G.M., Zamecnik, Patrik, Privé, Bastiaan M., Israël, Bas, Rijpkema, Mark, Scheenen, Tom, Barentsz, Jelle O., Nagarajah, James, Gotthardt, Martin
Publicado 2021

An Explorative Study of the Incidental High Renal Excretion of [(18)F]PSMA-1007 for Prostate Cancer PET/CT Imaging

por Allach, Youssra, Banda, Amina, van Gemert, Willemijn, de Groot, Michel, Derks, Yvonne, Schilham, Melline, Hoepping, Alexander, Perk, Lars, Gotthardt, Martin, Janssen, Marcel, Nagarajah, James, Privé, Bastiaan M.
Publicado 2022

[(89)Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates

por Rosar, Florian, Schaefer-Schuler, Andrea, Bartholomä, Mark, Maus, Stephan, Petto, Sven, Burgard, Caroline, Privé, Bastiaan M., Franssen, Gerben M., Derks, Yvonne H. W., Nagarajah, James, Khreish, Fadi, Ezziddin, Samer
Publicado 2022

Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of (177)Lu‐PSMA‐617 in prostate cancer patients

por Siebinga, Hinke, Privé, Bastiaan M., Peters, Steffie M. B., Nagarajah, James, Dorlo, Thomas P. C., Huitema, Alwin D. R., de Wit‐van der Veen, Berlinda J., Hendrikx, Jeroen J. M. A.
Publicado 2023

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation

por Peters, Steffie M. B., Mink, Maaike C. T., Privé, Bastiaan M., de Bakker, Maarten, de Lange, Frank, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Gotthardt, Martin, Nagarajah, James, Konijnenberg, Mark W.
Publicado 2023

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry

por Uijen, Maike J.M., Privé, Bastiaan M., van Herpen, Carla M.L., Westdorp, Harm, van Gemert, Willemijn A., de Bakker, Maarten, Gotthardt, Martin, Konijnenberg, Mark W., Peters, Steffie M.B., Nagarajah, James
Publicado 2023

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

por Privé, Bastiaan M., Boussihmad, Mohamed A., Timmermans, Bart, van Gemert, Willemijn A., Peters, Steffie M. B., Derks, Yvonne H. W., van Lith, Sanne A. M., Mehra, Niven, Nagarajah, James, Heskamp, Sandra, Westdorp, Harm
Publicado 2023

Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome

por Peters, Steffie M. B., Privé, Bastiaan M., de Bakker, Maarten, de Lange, Frank, Jentzen, Walter, Eek, Annemarie, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Gotthardt, Martin, Nagarajah, James, Konijnenberg, Mark W.
Publicado 2021

[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment

por Peters, Steffie M. B., Hofferber, Regina, Privé, Bastiaan M., de Bakker, Maarten, Gotthardt, Martin, Janssen, Marcel, de Lange, Frank, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Costa, Pedro F., Nagarajah, James, Konijnenberg, Mark W., Jentzen, Walter
Publicado 2021

PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study

por Banda, Amina, Privé, Bastiaan M., Allach, Youssra, Uijen, Maike J. M., Peters, Steffie M. B., Loeff, Cato C., Gotthardt, Martin, Muselaers, Constantijn H. J., Witjes, J. Alfred, van Oort, Inge M., Sedelaar, J. P. Michiel, Westdorp, Harm, Mehra, Niven, Khreish, Fadi, Ezziddin, Samer, Sabet, Amir, Kreissl, Michael C., Winkens, Thomas, Seifert, Philipp, Janssen, Marcel J. R., van Gemert, Willemijn A. M., Nagarajah, James
Publicado 2022

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

por Privé, Bastiaan M., Janssen, Marcel J. R., van Oort, Inge M., Muselaers, Constantijn H. J., Jonker, Marianne A., de Groot, Michel, Mehra, Niven, Verzijlbergen, J. Fred, Scheenen, Tom W. J., Zámecnik, Patrik, Barentsz, Jelle O., Gotthardt, Martin, Noordzij, Walter, Vogel, Wouter V., Bergman, Andries M., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Gerritsen, Winald R., Witjes, J. Alfred, Nagarajah, James
Publicado 2020

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial

por Privé, Bastiaan M., Janssen, Marcel J. R., van Oort, Inge M., Muselaers, Constantijn H. J., Jonker, Marianne A., van Gemert, Willemijn A., de Groot, Michel, Westdorp, Harm, Mehra, Niven, Verzijlbergen, J. Fred, Scheenen, Tom W. J., Zámecnik, Patrik, Barentsz, Jelle O., Gotthardt, Martin, Noordzij, Walter, Vogel, Wouter V., Bergman, Andries M., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Gerritsen, Winald R., Witjes, J. Alfred, Nagarajah, James
Publicado 2021